Race Oncology CEO Phillip Lynch and CSO Dr Daniel Tillett present Race's June 2022 Quarterly Investor Briefing followed by a Q&A session. https://youtu.be/41g0MngwCrU

June-2022-Quarterly-Activity-ReportDownload

30 June 2022 – Race Oncology Limited (“Race”) is pleased to share further interim results from our preclinical cardioprotection program in collaboration with researchers from the University of Newcastle (ASX…

28 June 2022 – Race Oncology Limited (“Race”) is pleased to share the final results from our preclinical melanoma research program in collaboration with the University of Newcastle (ASX announcement:…

https://youtu.be/XCrwvbUZiWM